Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment

ABSTRACT

A hallmark of pancreatic ductal adenocarcinoma (PDAC) is an exuberant stroma comprised of diverse cell types that enable or suppress tumor progression. Here, we explored the role of oncogenic KRAS in protumorigenic signaling interactions between cancer cells and host cells. We show that KRAS mutation (KRAS*) drives cell-autonomous expression of type 1 cytokine receptor complexes (IL2γ–IL4α and IL2γ–IL13α1) in cancer cells that in turn are capable of receiving cytokine growth signals (IL4 or IL13) provided by invading Th2 cells in the microenvironment. Early neoplastic lesions show close proximity of cancer cells harboring KRAS* and Th2 cells producing IL4 and IL13. Activated IL2γ–IL4α and IL2γ–IL13α1 receptors signal primarily via JAK1–STAT6. Integrated transcriptomic, chromatin occupancy, and metabolomic studies identified MYC as a direct target of activated STAT6 and that MYC drives glycolysis. Thus, paracrine signaling in the tumor microenvironment plays a key role in the KRAS*-driven metabolic reprogramming of PDAC.

SIGNIFICANCE: Type II cytokines, secreted by Th2 cells in the tumor microenvironment, can stimulate cancer cell–intrinsic MYC transcriptional upregulation to drive glycolysis. This KRAS*-driven heterotypic signaling circuit in the early and advanced tumor microenvironment enables cooperative protumorigenic interactions, providing candidate therapeutic targets in the KRAS* pathway for this intractable disease.

INTRODUCTION

Oncogenic KRAS mutation (KRAS*) is a signature genetic alteration in human pancreatic ductal adenocarcinoma (PDAC). Genetically engineered mouse models have validated a critical role of KRAS* in both the initiation and maintenance of PDAC (1–3). KRAS* alone has been shown to cause acinar cell dysplasia or acinar-to-ductal metaplasia (ADM) and, together with inflammatory injury (e.g., cerulein-induced pancreatitis) and/or tumor suppressor deficiencies (e.g., INK4a/ARF, TP53, and/or SMAD4 loss), promotes the malignant transformation of these initiated preneoplastic lesions into high-grade pancreatic intraepithelial neoplasia (PanIN) and frank adenocarcinoma. Most studies to date have focused on cooperative cancer cell–intrinsic oncogenic genetic alterations that drive growth factor–independent proliferation and enhanced survival of cancer cells. In addition, although a growing body of evidence has revealed a key role for cancer-intrinsic oncogenic signals in driving the recruitment of suppressive immune cells to constrain antitumor immunity, whether and how these infiltrating immunocytes might, in turn, provide additional trophic support for these KRAS*-initiated cancer cells to enable cancer progression is less well defined.

A hallmark feature of PDAC is an extensive desmoplastic stroma comprised of fibroblasts, extracellular matrix (ECM), and immune cells (4–6). Studies have reported both the presence (7, 8) and absence (5, 9) of infiltrating effector immune cells in the PDAC tumor microenvironment (TME), with lymphocyte infiltrates confined mostly to the stromal compartment. The biological relevance of these lymphocytes is suggested by the observation that the presence of a T-cell coinhibitory gene expression pattern is inversely correlated with survival (10). To date, studies exploring the role of lymphocytes in PDAC biology have focused largely on their immunologic functions in constraining tumor initiation and progression. Beyond their role in immune suppression, infiltrating immune cells may also function to support the initiation and growth of PDAC. In the case of CD4+ T cells that are present in malignant lesions (as in this study), some of its subtypes (Th2, Th17, Treg) are known to play critical roles in inflammatory processes in cancer (11, 12), and Th2 subtypes can promote tumor growth via induction of polarization of M1 macrophages into immune-suppressive M2 macrophages (13).

Exploration of the cross-talk between various cells and their factors in the PDAC TME in processes of tumor initiation and progression represents an area of active investigation. Here, we specifically explored the cooperative interactions between mutant-KRAS signaling in cancer cells and cytokines derived from the tumor microenvironment, specifically infiltrating...
Th2-polarized CD4+ T cells, in preneoplastic lesions (PanIN) and PDAC. We established that KRAS* drives the expression of cytokine receptors, which are in turn activated by cytokines produced predominantly by infiltrating Th2 cells. Ligand-induced activation of cytokine receptor signals via the JAK–STAT pathway to directly upregulate MYC, which in turn drives metabolic reprogramming by the upregulation of glycolytic genes. This paracrine pathway contributes to KRAS*-driven glycolysis and provides potential therapeutically targetable interactions in the PDAC TME.

**RESULTS**

**KRAS*** Upregulates Specific Type I Cytokine Receptor Family Members

The iKRAS* model enables temporal and spatial control of KRAS* in PDAC via doxycycline (Fig. 1A). Upon extinction of mutant KRAS in established tumors, we observed significant rapid changes in the TME, prompting us to explore KRAS*-dependent signaling interactions within and across cancer and host cells (Supplementary Fig. S1A). Gene set enrichment analysis (GSEA) comparisons of KRAS* parental cancer cell lines versus KRAS*-negative repressed cancer cell lines (KRAS** vs. KRAS*; ref. 3) identified IL2 and IL2I as top oncogenic signature pathways upregulated in the KRAS** cell lines (Fig. 1B and C). Similarly, comparison of cell lines “On” versus 24 hours “Off” doxycycline shows enrichment of IL2, IL15, and IL21 gene signatures in the KRAS*-dependent escapee lines (Supplementary Fig. S1B–S1D). We then audited microarray expression patterns of verifiable mouse cytokine genes (~650) in KRAS* “On” versus “Off” cell lines derived from an autochthonous iKRAS* tumor. Among the top 25 KRAS*-upregulated cytokine network genes were IL2Rγ along with one of its family members, IL4Rα (Fig. 1D). Finally, meta-analysis of human PDAC identified IL2Rγ as one of the top 50 most overexpressed genes in PDAC tumors (14).

IL2Rγ and IL4R are members of a common gamma chain receptor (γ, or CD132) family, which is part of a larger superfamily known as the type I cytokine receptor superfamily. IL4 binds to IL4R receptor (CD124; ref. 15), which then recruits the IL2Rγ chain receptor to form a functional type I IL4R receptor (Supplementary Fig. S1E). In addition, IL2Rγ can heterodimerize with the other private coreceptors IL2R, IL7R, IL9R, IL15R, and IL21R to engage the specific cytokines IL2, IL7, IL9, IL15, and IL21, respectively (16). Examination of the type I cytokine receptor family showed that only IL2Rγ and IL4Rα were regulated by KRAS* (Fig. 1E). Analysis of human PDAC datasets in Oncomine (datasets from following publications: PMIDs 12750293, 15867264, 19732725, and 19260470) also showed IL2Rγ and IL4R overexpression in PDAC relative to normal pancreas (Fig. 1F). Next, we performed digital microdissection of RNA-sequencing (RNA-seq) data of The Cancer Genome Atlas (TCGA) PDAC datasets to identify those cells expressing IL2Rγ and IL4R, which can also be expressed in T cells, macrophages, eosinophils, and basophils. This approach enabled assignment of the source of IL2Rγ to cancer cells and its correlation with mutant-KRAS expression (Supplementary Fig. S1F). Examination of human PDAC samples (n = 121) showed that approximately 95% of patients variably overexpress low to high levels of IL2Rγ and IL4R relative to normal tissues (Fig. 1G and H). Thus, these type I cytokine receptor family members are consistently upregulated in mutant KRAS-expressing human and murine PDAC.

**IL4Rα and Not IL2Rγ Contributes to PDAC Progression In Vivo**

IL2Rγ and IL4Rα are overexpressed in PDAC, where their expression is KRAS* dependent (Fig. 2A; Supplementary Fig. S2A and S2B). Notably, although IL2Rγ gene expression is not necessary for in vitro cell proliferation (Fig. 2B and C; Supplementary Fig. S2C), inhibition of IL2Rγ in an in vivo syngeneic orthotopic mouse model caused a modest decrease in tumor burden, albeit with rapid recurrence and thus only a modest survival benefit (median survival 32 days compared with 29 days for control tumor; Fig. 2D; Supplementary Fig. S2D–S2F). Decreased tumor burden aligns with previous reports that shRNA-mediated IL2Rγ depletion provokes tumor regression (17). These modest antitumor results raise the possibility that either IL2Rγ plays a marginal role in tumor growth, or an alternate receptor complex or pathway is available to sustain growth and survival signals. Along these lines, the IL4Rα receptor can engage the IL4 ligand via two distinct receptor complexes, type I and II IL4Rα receptors, depending on its dimerization partner. Both type I (IL2Rγ and IL4Rα) and type II (IL4Rα and IL13Rα1) can bind with IL4 and activate its downstream JAK–STAT pathway; however, each complex utilizes distinct JAK kinases and STAT transcription factors (Fig. 2E). We therefore tested and determined that both IL4Rα (Fig. 2F) and IL13Rα1 were indeed regulated by KRAS* (Fig. 2A); specifically, these receptors were among the top 25 cytokine genes regulated by KRAS* (Fig. 1D). The expression of both IL4Rα and IL13Rα1 was lost upon extinction of KRAS* in the iKRAS* mouse model (Supplementary Fig. S2G). We also validated that IL13Rα1 was upregulated in multiple human PDAC tumor datasets compared with PanIN or a nonmalignant part of the pancreas parenchyma (Fig. 2F). In contrast to the modest antitumor impact of IL2Rγ depletion above, shRNA-mediated depletion of IL4Rα led to significant tumor regression and increased survival (median survival 60 days compared with 30 days for control tumor; Fig. 2G and H; Supplementary Fig. S2H and S2I). There was also a significant decrease in the proliferation marker PCNA upon IL4Rα depletion (Fig. 2I). The above findings suggest that IL4Rα is a central node for the dual signaling arising from IL4 or IL13, and contributes to PDAC tumorigenesis.

**PDAC Cells Are Responsive to IL4 and IL13 Cytokines Which Drives JAK–STAT–MYC Activation**

Thorough analysis of all γ, cytokine family members (IL2, IL4, IL7, IL9, IL15, and IL21) and IL13 genes revealed that none of the cytokines except IL15 was regulated by KRAS* (Fig. 3A). This led us to speculate that γ, cytokines may be sourced instead from host cells in the TME. It is well established that ligand-induced dimerization of cytokine receptors leads to cross-phosphorylation of tyrosine residues in JAKs, which in turn interact with the SH2 domain of the STAT transcription factors, leading to STAT phosphorylation, homodimerization, and activation (18). To examine ligand-induced activation and downstream signaling, we systematically analyzed the capacity of the above cytokines to activate any of the four mammalian...
Cytokines Mediated Tumor Progression in PDAC

**Figure 1.** KRAS\(^{+}\) upregulates specific type I cytokine receptor family members. A, Construct of the inducible KRAS\(^{G12D}\) transgenic mouse alleles (top). Strategy to generate iKRAS\(^{+}\) cell lines followed by transcriptome analysis. B, GSEA of oncogenic pathways. Pathways of interest IL2, IL15, and IL21 are highlighted in blue and indicated with red arrow. Nominal \(P\) values (Nom \(P\)) are shown on the right side of the bar graph. C, Relative expression of common \(\gamma\) chain receptor family members. D, Differential expression (log2) of IL2RG and IL4R genes from human Oncomine datasets. E, Relative expression of common \(\gamma\) chain receptor family genes regulated by KRAS. **Results** are shown as mean \(\pm\) SEM. \(P\) values were calculated using Student \( t \) test (ns, not statistically significant). Differential expression (log2) of IL2RG and IL4R genes from human Oncomine datasets. **Results** are shown as mean \(\pm\) SEM. \(P\) values were calculated using Student \( t \) test (ns, not statistically significant). O/E, overexpression. G, Normal (left) and two representative (right two panels) IHC of IL2R\(\gamma\) and IL4R in human samples (\(n = 121\)) showing membrane expression of both proteins. Scale bars, 50 \(\mu\)m and 100 \(\mu\)m. H, Quantification and statistical analysis of the IHC data from above. Low levels of IL2R\(\gamma\) and IL4R are expressed in normal pancreas, mostly by the islet cells, whereas moderate to high level of expression is observed in PDAC. Statistical analysis of the patient samples is shown in the table to the right of graph.
Figure 2. IL4Ra and not IL2Rγ contributes to PDAC progression in vivo. A, mRNA expression of KRAS, IL2Rγ, IL4Ra and IL13Ra1 upon treatment with MEK1/2 (CI-1040 and trametinib) and PI3K (BKM120) inhibitors. Also shown are the mRNA expression of GM-CSF, E-cadherin, and ITGB6, known downstream regulated genes of KRAS and PI3K. B, Schematic of the vector construct used to generate luciferase receptor cell lines and shRNA knockdown of IL2Rγ (top). Schematic of orthotopic syngeneic mouse model in C57BL/6 mice (bottom). C, mRNA expression of IL2Rγ in mouse tumor cell lines transfected with shRNA for IL2Rγ (clone #1 and #2) or control vector. D, Kaplan–Meier survival curves of mice transplanted with mouse tumor cell lines transfected with shRNA for IL2Rγ or control vector (n = 10). Survival statistics were calculated using log-rank (Mantel–Cox) test; P < 0.0001. E, Schematic of IL2Rγ–IL4R and IL13Ra1–IL4R pathways. F, Differential expression (log2) of IL13Ra1 in human Oncomine datasets. Results are shown as mean ± SEM. *P values were calculated using Student t test (ns, not statistically significant). O/E, overexpression. G, mRNA expression of IL4Ra in mouse tumor cell lines transfected with shRNA for IL4Ra (clone #88 and #89) or control vector. H, Kaplan–Meier survival curves of mice transplanted with mouse tumor cell lines transfected with shIL4Ra#88 (n = 11), shIL4Ra#89 (n = 12), or control vector (n = 16). Survival statistics were calculated using log-rank (Mantel–Cox) test; P < 0.0001. I, Representative hematoxylin and eosin (H&E) and PCNA staining of orthotopic tumor of mouse transfected with shIL4Ra or shCtrl cell lines. Scale bars, 50 μm.
IL4 and IL13 were the only ligands capable of activating the downstream effectors: specifically, JAK1 (Yer1034/1035) and TYK2 (Yer1054/1055) kinases as well as STAT6 (Yer641) and STAT5 (Yer694; Fig. 3B; Supplementary Fig. S3A). Consistently, IL4 treatment also activated STAT6 in most human PDAC cell lines tested (Supplementary Fig. S3B).

Third, inhibition of IL2Rγ using neutralizing antibodies showed no change in JAK1 or STAT6 phosphorylation, and moderate decrease in pTYK2 and pSTAT5, indicating that IL4 signaling via IL2Rγ–IL4Rα receptors utilized the TYK2–STAT5 pathway, whereas signaling via IL13Rα1–IL4R utilized the JAK1–STAT6 pathway (Fig. 3C). Also, inhibition of IL2Rγ receptor had no effect on IL13 ligand–mediated JAK1–STAT6 activation, indicating that IL13 does not utilize the IL2Rγ–IL4Rα receptor pathway (Supplementary Fig. S3C).
This strong activation of the JAK1–STAT6 signaling pathway prompted functional analysis of this pathway on cancer cell survival and tumorigenesis. Specifically, IL4 (10 ng/mL) or IL13 (10 ng/mL) treatment of iKRAS* cell lines increased proliferation (Fig. 3D). To recapitulate the in vivo condition, an ex vivo organoid model from Pdx-Cre;LSL-Kras mice was generated (Fig. 3E). Upon characterization, the organoid was identified as being derived from mouse progenitor cells as evidenced by DCLK1 expression and is also positive for epithelial marker, as shown in pan-cytokeratin (Pan-CK; Fig. 3F). Following both IL4 and IL13 treatment, RNA-seq analysis was performed, revealing that the top enriched genes based on CPM (log2) versus P value (−log10) showing Myc as the top enriched gene. GSEA of oncogenic pathways showing Myc as one of the top targets. L, ChIP-seq of STAT6 showing binding of STAT6 on the cis-element of Myc. M, Consensus sequence of STAT6 binding site on the Myc cis-regulatory element.

IL4 and IL13 Upregulate MYC to Promote Metabolic Reprogramming

Oncogenic MYC is known to cooperate with KRAS* in driving many cancers and contributes to many cancer hallmarks (21, 22), including cancer cell survival (23, 24), cancer initiation and progression (24, 25), and metabolic reprogramming of bioenergetic pathways such as glutamine (26) and glucose (27) metabolism to support anabolic processes. As our previous work in the iKRAS* model demonstrated an enrichment of MYC E-box binding elements in many genes governing glucose and glutamine metabolism (1), we performed targeted metabolic analysis following a 1-hour treatment of IL4 or IL13 (10 ng/mL) in iKRAS* cells. We observed increased glucose metabolism leading to increased production of pyruvate (Fig. 4A). These findings contrast with earlier in vitro studies showing that glucose catabolism in PDAC is directed toward the tricarboxylic acid (TCA) cycle. It is interesting to note that in vivo metabolism studies in PDAC and other cancer types have definitively shown both glucose and glutamine are utilized by tumors compared to in vitro where PDAC cells are mostly dependent on glutamine (28, 29). Thus, we considered the possibility that the presence of cancer cell–extrinsic factors in the TME that include cytokines might contribute to the dose-dependent effect on tumor-cell proliferation (19, 20), the finding that IL4 could elevate Myc expression in PDAC cells reinforces the hypothesis of a tumor-promoting role for IL4.

Figure 3. (Continued) I, Heat maps of the genes enriched in indicated genes upon treatment of cells with IL4 (10 ng/mL) or IL13 (10 ng/mL) for 1 hour. Expression levels shown are representative of log2 values of each replicate from either vehicle or IL4 treated cultured cell lines. Red signal denotes higher expression relative to the mean expression level within the group, and green signal denotes lower expression relative to the mean expression level within the group. veh, vehicle. J, Quantification of the enriched genes based on CPM (log2) versus P value (−log10) showing Myc as the top enriched gene. K, GSEA of oncogenic pathways showing Myc as one of the top targets. L, ChIP-seq of STAT6 showing binding of STAT6 on the cis-element of Myc. M, Consensus sequence of STAT6 binding site on the Myc cis-regulatory element.
Figure 4. IL4/IL13 upregulates MYC to promote metabolic reprogramming. **A,** Heat map of those metabolites that were significantly and consistently changed upon treatment of IL4 or IL13 in two KRAS* cell lines as determined by targeted LC/MS-MS. Cells were treated with IL4 or IL13 for 1 hour, at which point metabolite levels were measured from triplicates for each treatment condition. The averaged ratios of differentially regulated metabolites are represented in the heat map (differential FDR < 0.25). Arrows indicate metabolites involved in glucose metabolism that were regulated upon IL4 or IL13 treatment. **B,** Immunoblot analysis for HK-II, enolase I, MYC, pSTAT6, STAT6, pJAK1, and JAK1, and 1 cells treated with IL4 (10 ng/mL) for indicated times. β-actin acts as a loading control. C, IHC of HK-II and enolase I in preneoplastic mouse (**C**). Schematic of KRAB-dCas9 (bottom left). Immunoblot showing loss of IL4Ra with CRISPR-Cas9 treatment (**D**). E, Seahorse analysis for ECAR of cells treated with IL4 (1–10 ng/mL) for 1 hour. F, Quantification of the Seahorse data on the left. Results are shown as mean ± SEM. P values were calculated using Student t test. **G,** Diagram of glycolysis and TCA cycle. Blue circles indicate 13C-labeled sites. Red label indicates metabolites measured using mass spectrometry. **H,** Percentage labelling of 13C-labeled sites in metabolites indicated. Data are presented as mean ± SEM. n = 4. Two-tailed t test was used for all comparisons between two groups. **I,** Consensus sequence of STAT6-binding site on the Myc cis-regulatory element (top left). Schematic of KRAB-dCas9 (bottom left). Immunoblot showing loss of IL4-mediated regulation of MYC and HK-II upon binding of KRAB-dCas9 on the Myc cis-regulatory element, which blocks the binding of STAT6 to the consensus cis-element. Actin acts as a loading control. PAM, protospacer adjacent motif.
in vivo metabolic pathway profile. Consistent with increased glycolysis upon IL4 or IL13 treatment, we observed increased expression of the glycolytic genes hexokinase II (HK-II), and enolase I (Fig. 4B). The strong expression of HK-II and enolase I is also observed in the epithelial compartment of premalignant tumor models, alluding to upregulation of specific glycolytic genes (Fig. 4C) which are known MYC targets. Knockdown of IL4Ra in syngeneic orthotopic tumors caused a decrease in MYC and a concurrent decrease in HK-II and enolase I expression (Fig. 4D; Supplementary Fig. S4A and S4B). Using the Seahorse glycolysis stress test, we further analyzed the glucose consumption rate upon addition of IL4 and IL13 and detected a substantial increase in extracellular acidification rate (ECAR), which is an indication of acidification of the media upon conversion of glucose to lactate, and a net increase in protons in the spent media (Fig. 4E and F). Moreover, 13C-glucose (Glc) tracing analysis showed that IL4 reprograms the glycolytic pathway by diverting more glucose-carbon toward energy production via the TCA cycle and less toward the PPP. We saw an enrichment in 13C-isotope labeling in glycolysis and TCA cycle intermediates such as pyruvate, fumarate, and oxaloacetate (OAA). There was a simultaneous decrease in 13C-isotope labeling in PPP intermediates such as ribose-5-phosphate and sedoheptulose-7-phosphate (Fig. 4G and H). Together, these findings support the view that IL4 and IL13 drive energy production via glycolysis and the TCA cycle.

We further validated whether IL4 acts through MYC or directly regulates the metabolic enzymes HK-II and enolase I. To test this hypothesis, we have utilized a catalytically inactive Cas9 (dCas9) fused to transcriptional repressor/chromatin effector domains (KRAB) allowing silencing of a genomic region of interest. We designed small guide RNA (sgRNA) that would target the STAT6 binding site of a genomic region of interest. We designed small guide RNA (sgRNA) that would target the STAT6 binding site approximately 350 kb upstream of the Myc cis-regulatory element. We performed chromatin effector domains (KRAB) allowing silencing of a genomic region of interest. We designed small guide RNA (sgRNA) that would target the STAT6 binding site approximately 350 kb upstream of the Myc cis-regulatory element approximately 350 kb upstream of the Myc promoter region. Immunoblot shows that upon silencing of the STAT6 binding region, IL4-mediated regulation of MYC and HK-II is lost; however, the baseline expression of MYC remains intact, indicating alternate regulation of baseline MYC and HK-II expression (Fig. 4I). Similarly, using ruxolitinib, a JAK1-specific inhibitor, shows that upon inhibition of JAK1–STAT6 signaling, the IL4-mediated upregulation of MYC and HK-II is abolished (Supplementary Fig. S4C).

The Tumor Microenvironment Supplies IL4 and IL13

As IL4 and IL13 drive cancer-cell proliferation in vivo in our model, we sought to identify the source of these cytokines in the TME. IHC confirmed elevated IL4 and IL13 in KRAS*-Off tumors compared with KRAS*-On tumors or normal pancreas (Supplementary Fig. S5A). IL4 and IL13 are known to be secreted primarily by Th2-polarized CD4+ T cells and to a lesser extent by mast cells, eosinophils, and stromal cells (30). The Th2 cells secrete IL4 and IL13 in a paracrine fashion, polarizing additional naïve CD4+ T cells to Th2 type (31). Importantly, flow cytometry analysis showed that 40% to 60% of the live cells in the PDAC tumor were CD45+ cells, of which 18% to 20% were CD4+ cells and a majority of those were CD4+ cells (Fig. 5A; Supplementary Fig. S5B–S5D). Next, mass cytometry by time-of-flight (CyTOF) was used to conduct a comprehensive immune profile of mouse PDAC tumors (on doxycycline for 12 weeks) and compare these profiles with those of normal pancreas and spleen (Fig. 5B; Supplementary Fig. S5E). Correspondingly, using multiplexed imaging mass spectrometry (iMS), human PDAC tissues also showed significant infiltration of CD4+ T cells (Fig. 5C and D). These findings are consistent with recent reports that antitumor immune response is dependent on the presence of the right proportion of T effector (Th1 and CD8+) cells versus tumor-promoting T (Treg, Th2, Th17) cells (10, 32). Expression of the transcription factors Tbet and GATA3 is used for molecular subtyping of Th1 cells and Th2 cells, respectively (33). Molecular characterization of the specific type of infiltrating CD4+ T cells shows that most infiltrating CD4+ T cells were GATA3+ Th2 cells and only a small fraction were Tbet+ Th1 cells (Fig. 5E and F; Supplementary Fig. S5F). Single-cell analysis of low- and high-grade intraductal papillary mucinous neoplasm (IPMN) and PDAC patient samples revealed CD4+ T-cell infiltration and that a higher percentage of the CD4+ T cells are GATA3+ Th2 subtypes compared with Tbet+ Th1 cells (Fig. 5G and H; Supplementary Fig. S5G).

Given the paucity of T cells in the TME of advanced PDAC and that KRAS mutational activation is an early event in PDAC tumorigenesis, we also assessed whether Th2 cells infiltrate during very early stages of the neo-neoplastic process and potentially cooperate with KRAS* to drive tumorigenesis. We utilized the Pdx-Cre;LSL-KrasG12D model, which generates ADM and PanIN lesions at 3 to 6 months of age; these neoplasms rarely progress to advanced malignancy following a long latency (34). IL4rα and IL13rα expression as well as activated STAT6 and elevated MYC levels were readily detected in the KrasG12D, expressing neoplastic cells (Fig. 6A)—findings consistent with a potential role of IL4 and IL13 during early stages of tumorigenesis. Also, these PanIN-like lesions were infiltrated by CD4+ T cells, which were also mostly Th2 type (GATA3+; Fig. 5I; Supplementary Fig. S5F) as the GATA3:Tbet ratio was skewed toward the Th2 phenotype. On the basis of these findings, we speculated that infiltrating Th2 cells...
Cytokines Mediated Tumor Progression in PDAC

**A** Murine T cells are predominantly CD4+ type

**B** CyTOF of murine tumor

**C** Human PDAC tissue mass cytometry imaging (iMC)

**D** Analysis of T-cell infiltration (iMC)

**E** Stained cells CD4+ per FoV

**F** GATA3+CD4+ T cells infiltrate murine PanIN

**G** scRNA-seq analysis of T cells in human PDAC

**H** Ratio of GATA3/Tbet

---

**RESEARCH ARTICLE**

**APRIL 2020**

**CANCER DISCOVERY** | 617
Figure 6. JAK1–STAT6 pathway promotes cancer cell proliferation and tumor growth. A, Representative H&E and IHC analysis of pERK, IL13Rα1, pSTAT6, and MYC in the preneoplastic pancreas. The bottom panels are amplified images of those above. Scale bars, 100 μm (top) and 50 μm (bottom). Representative luciferase images of comparing anti-HRP versus anti-IL4 (n = 10), imaged at day 4. B, Immunoblot of pSTAT6 and STAT6 upon treatment with IL4 or IL13 followed by treatment with ruxolitinib, a specific JAK1 inhibitor. β-actin acts as a loading control. C, Proliferation assay of iKRAS* cell lines upon treatment with IL4 or IL13 and followed by treatment with ruxolitinib (Ruxo; JAK1 inhibitor) and tofacitinib (Tofa; JAK2/3 inhibitor). D, Strategy for CRISPR/Cas9 knockdown of Jak1 in mouse pancreas cell line. Immunoblot of JAK1 in two separate single clones of Jak1 knockout cell lines. β-actin acts as a loading control. E, Tumor volume of transplanted tumor upon CRISPR/Cas9 knockout (KO) of Jak1 compared with scrambled control (n = 5). F, Kaplan–Meier survival curves of mice transplanted with mouse tumor cell lines transfected with CRISPR/Cas9 knockout of Jak1 or control cell lines (n = 10). G, Proposed model of IL4–JAK1–STAT–MYC signaling cascade that includes KRAS-mediated upregulation of IL4–IL2Rγ and IL4–IL13Rα1 receptors and infiltration of Th2 cells into the TME.
Cytokines Mediated Tumor Progression in PDAC

contribute to pancreatic cancer initiation and progression. Accordingly, a regimen of 12 doses of anti-CD4 neutralizing antibody treatment of Pdx-Cre;LSL-Kras\(^{G12D}\) mice, starting at age 30 days, resulted in a decrease in size and number of PanIN lesions (Supplementary Fig. S6A). IHC staining of tissues derived from anti-CD4 treated mice showed a marked reduction in CD4\(^+\) T cells in the vicinity of the smaller PanIN lesions; moreover, these lesions show reduced expression of PCNA, HK-II, and enolase I in the cancer cells (Supplementary Fig. S6B).

**JAK1–STAT6 Pathway Promotes Cancer Cell Proliferation and Tumor Growth**

To assess the molecular and biological impact of these IL4- and IL13-secreting Th2 cells on cancer cell signaling, we inhibited IL4- or IL13-mediated JAK–STAT pathway activation using ruxolitinib, a specific JAK1/2 inhibitor, and tofacitinib, a specific JAK3 inhibitor. Consistent with the role of JAK1 above, ruxolitinib inhibited STAT6 phosphorylation (Fig. 6B) and abolished IL4- and IL13-mediated growth stimulation of PDAC cells, whereas tofacitinib had no effect on the IL4- and IL13-mediated proliferation. (Fig. 6C). Similarly, JAK1 ablation by CRISPR/Cas gene editing (Fig. 6D) displayed markedly reduced tumor growth with JAK1-null cancer cells relative to unedited isogenic controls and increased survival (median survival 40 days; Fig. 6E and F). These genetic studies of inhibition of the JAK1 pathway support the role of the JAK1–STAT6 pathway in promoting PDAC growth. Of note, although anti-IL4 neutralizing antibody reduced tumor burden, these responses were not durable and the mice eventually succumbed to tumor recurrence (Supplementary Fig. S6C–S6E), suggesting that IL13 can complement IL4 function, and any attempt to target the Th2 signaling would likely require neutralizing both IL4 and IL13 cytokines. Alternatively, IL4R, the common receptor for IL4/IL13 signaling, may be an attractive target, as this intervention would block the signal emanating from both IL4 and IL13.

**DISCUSSION**

KRAS* plays a central role in PDAC initiation and maintenance through a variety of mechanisms involving its well-established autonomous cancer cell signaling functions. In this study, we show that a novel tumor-promoting function of KRAS* involves establishment of a paracrine circuit utilizing T-cell cytokines in the PDAC TME. Specifically, KRAS* is shown to regulate cytokine receptor expression in cancer cells and infiltrating T cells provide cytokines to activate these receptors, which in turn provide cytokine receptors and TME cytokines to support cancer cell metabolic reprogramming. Targeting components of this mutant KRAS-regulated pathway provides testable therapeutic targets for indirectly disrupting KRAS*-driven tumorigenesis.

Most work to date has focused on the classic role of IL4 in promoting tumor progression via activation of immune-suppressive macrophages (M2 polarization; refs. 13, 35), which in turn directly enhances cancer progression and metastasis via secretion of immuno suppressive molecules such as IL10 and TGFβ. This study, and the work of others (36), expands the role of IL4 in the context of KRAS*-driven PDAC through its promoting cancer cell proliferation via mutant KRAS-mediated upregulation of cytokine receptors such as IL4R, IL2Rγ, and IL13Rα1, which in turn enables IL4 and IL13 cytokine activation of the JAK1–STAT6–MYC pathway in cancer cells. MYC upregulation promotes cancer cell proliferation (37) and metabolic reprogramming characterized by increased glucose utilization as well as activation of the core glycolytic pathway (38). Importantly, MYC is required for metabolic reprogramming, as its loss has been shown to diminish expression of key metabolic genes required for maintaining the abovementioned metabolic pathways (1). In view of the MYC upregulation observed in our current study, we investigated its effect on metabolic genes. Following IL4 treatment, our work confirmed enhanced glycolytic pathway activity followed by an increase in TCA cycle intermediates and diminished PPP intermediates, a feature that is known to be attributed to MYC activation (38). This finding aligns convincingly with recent in vivo metabolic studies in various cancer models, where glucose is an important source of energy (39, 40).

Our findings emphasize the critical nature of TME-derived cytokines in shaping the metabolic landscape of cancer cells and further suggest that the absence of cytokines in the in vitro setting could account for the metabolic shift of cancer cells to glutaminolysis in cell culture (41). Overall, our prior work (1) and current study emphasize that KRAS and IL4 both can regulate MYC protein via distinct and reinforcing mechanisms. KRAS is known to regulate MYC protein stability via phosphorylation at site S62 (42), which inhibits proteasomal degradation of MYC. Moreover, in our prior work (1) we observed that glycolytic genes that are upregulated with KRAS* possess MYC binding elements in the promoter. In our current study, we extend our understanding of how KRAS regulates MYC by showing that KRAS also regulates a cytokine circuit that results in the transcriptional upregulation of MYC via activated STAT6 engagement of the upstream enhancer element of the MYC locus.

Factors secreted by cancer cells, especially cytokines such as GM-CSF, G-CSF, etc., have been long associated with the recruitment of leukocytes into the TME, which creates a tumor-permissive niche for cancer cells to thrive (43, 44). Of special interest are T cells, because of their therapeutic potential via immune checkpoint blockade inhibition (ICI). Unfortunately, the PDAC microenvironment lacks sufficient effector immune cells to mount antitumor immunity for any therapeutic benefit. At the same time, recent clinical studies suggest that lymphocyte function may remain an important determinant of clinical outcome, as evidenced by the expression of the inhibitory immune checkpoint genes that inversely correlate with survival. We speculate that the localization of lymphocytes in the stroma, but not in close proximity to cancer cells, might diminish their effector function and patient response to ICI therapy (10), yet still enable such immune cells to support tumor development via mechanisms elucidated in this study. That is, the current study emphasizes the presence of the various T-cell subtypes in the TME and highlights the possibility of distinct effects on tumorigenesis and cancer therapy responses. Generally, Th1 cells provide positive response to ICI such as with
anti-CTLA4 therapy (45, 46) and induction of CD8+ T-cell infiltration. Whereas polarization toward Th2 cells prevents tumor rejection and facilitates tumor growth (47), IL4 is one of the most abundant cytokines secreted by Th2 cells. Correspondingly, it is notable that patients with PDAC with infiltration. Whereas polarization toward Th2 cells prevents we detect approximately 12% to 14% (data not shown) of can also infiltrate preneoplastic lesions (48, 49). Accordingly, shown that other CD4+ T-cell subtypes, such as Th17 cells, can also infiltrate preneoplastic lesions (48, 49). Accordingly, we detect approximately 12% to 14% (data not shown) of CD4+Th17 cells in these early-stage lesions, although IL17RA expression in cancer cells is independent of KRAS* in our model. A variety of mechanisms have been identified by which cancer cells reap the benefit of an immune-rich microenvironment. It is well established that pro- and/or anti-inflammatory cytokines and chemokines sourced from various immune (50–52) and stromal compartments (53) can shape the TME and ultimately dictate the trajectory of tumor progression. These cytokines and chemokines are in a constant tussle to promote or oppose host immune responses, which can lead to tumor progression, metastasis, and chemoresistance (54). In addition, although KRAS* is critical for all stages of tumorigenesis from initiation to metastasis, challenges surrounding anti-mutant KRAS therapeutics, coupled with murine studies showing bypass of KRAS* dependency (3, 55), underscore the need for alternative strategies targeting KRAS*-dependent circuitry to treat pancreatic cancer. The results of this study raise the possibility that targeting the IL4–IL4R–JAK1–STAT6 signaling cascade at the level of the dual neutralization of IL4/IL13 cytokines, IL4R receptor, JAK1, and/or STAT6 may provide such a therapeutic strategy (Fig. 6G). A phase II study, Ruxolitinib in Pancreatic Cancer Patients (RECAP), showed the median overall survival (OS) was significantly greater with ruxolitinib versus placebo. In a follow-up trial, two randomized, phase III studies, JANUS 1 and JANUS 2, were conducted to evaluate ruxolitinib in combination with capecitabine in patients with advanced/metastatic pancreatic cancer. However, the studies were terminated following a planned interim futility/effectiveness analysis of JANUS 1, because of lack of increase in OS (56). Overall, our study has provided an avenue to explore novel pancreatic cancer treatment based on the hallmarks of cancer that involve heterotypic collaborative interactions between cancer cells and the cells of the TME.

METHODS

Ethics Statement and Animal Modeling

All mouse manipulations were approved under MD Anderson Cancer Center’s Institutional Animal Care and Use Committee. All animals were maintained in pathogen-free conditions and cared for in accordance with the International Association for Assessment and Accreditation of Laboratory Animal Care policies and certification. All surgeries were performed with isoflurane anesthesia. Analgesic was administered after surgery along with temperature-controlled postsurgical monitoring to minimize suffering. TetO_Lox-Stop-Lox-KrasG12D (tetO_KrasG12D), ROSA26-LSL-rtTA-ires-GFP (ROSA_rtTA), p48-Cre, and LSL-Trp53 strains were described previously (1). Mice were back-crossed to the C57BL/6 background for more than eight generations to achieve a pure B6 mouse, and its purity and zygosity were validated by Charles River. Mice were maintained in pathogen-free conditions at MD Anderson Cancer Center (Houston, TX). Mice with spontaneous pancreas tumors were euthanized at designated time points for tumor collection. Owing to the internal location of these tumors, we used signs of lethargy, reduced mobility, and morbidity, rather than maximal tumor size, as a protocol-enforced endpoint.

Subcutaneous and Orthotopic Syngeneic Models

For all experiments, C57BL/6j (Stock 000664) mice, aged 4 to 6 weeks, were obtained from Jackson Laboratory unless otherwise mentioned. A 2 × 2 mm portion of the left abdomen was shaved to facilitate transplantation. Subcutaneous tumors were established by injection of 1 × 10⁶ cells into the flanks of mice. Tumor length and width were measured every 4 to 5 days and the volume was calculated according to the formula: Volume = (4/3) × 3.14 × (length/2) × (width/2). These experiments were not randomized, and the investigators were not blinded to allocation during experiments and outcome assessment. No statistical method was used to predetermine sample size. The cohort sizes for the study were estimated on the basis of previous experience using similar mouse models that showed significance.

Animals were euthanized for humane reasons when tumors were approximately 15 mm in diameter. Doxycycline was provided to the animals in the form of doxycycline water (doxycycline 2 mg/ml, sucrose 40 mg/ml) starting 2 days prior to transplantation. For orthotopic pancreas transplantation, mice were anesthetized using ketamine/xylazine. An incision was made in the left abdomen and the pancreas was gently exposed along with the spleen. Luciferase-expressing cells were slowly injected into the tail of the pancreas using a Hamilton syringe. Five microliters of cells (5 × 10⁶) mixed with 5 μL Matrigel was injected. For the orthotopic model, animals were imaged (IVIS Spectrum, PerkinElmer) 2 days after surgery to assess successful implantation of the tumors. Only orthotopic tumors of similar luciferase intensity were used further for the study. These criteria were preestablished. Furthermore, the animals were luciferase-imaged to monitor the progress of the tumor at different time points. Doxycycline water treatment was started 2 days after transplantation. Owing to the internal location of the tumors, we used signs of lethargy, reduced mobility, and morbidity, rather than maximal tumor size, as a protocol-enforced endpoint.

In Vivo Imaging

Live in vivo imaging was performed at the Small-Animal Imaging Facility at MD Anderson Cancer Center. MRI was performed using a Bruker ICON. For bioluminescence imaging, animals were anesthetized with isoflurane, injected intraperitoneally with 3 mg of β-luciferin (Perkin Elmer), and imaged using IVIS Spectrum Imaging System (Perkin Elmer). The Living Image 4.7 software (Perkin Elmer) was used for analysis of the images post acquisition.

Human PDAC Primary Tumor Samples

Human PDAC samples were obtained from MD Anderson’s Tissue Biobank. The samples were stained using the standard IHC protocol. The antibodies used were IL2Ry (Sigma Prestige HPA046641); IL4R (Bioss bs2458R); Tbet/TBX21 (CST 132325); and CD4 (Abcam ab133616). The stained samples were imaged using Panoramic 250 slide scanner, and data were analyzed by two independent
pathologists using Pannoramic viewer software (3DHISTECH Ltd). Human studies were approved by MD Anderson’s Institutional Review Board (IRB), and prior informed consent was obtained from all subjects under IRB protocol LAB05-0854.

**Digital Microdissection of TCGA Datasets**

Digital microdissection of TCGA datasets was done by analyzing the mRNA expression data. Pearson correlation analysis of RNA datasets was done by comparing KRAS expression with known T-cell signature genes (CD8, IL2Rγ, ICOS, GZMK). A significant positive correlation of KRAS with T-cell signature genes was considered as coexpression of the above genes in the same tissue compartment.

**Gene Expression Profiling and Computational Analysis**

Gene expression profiling was performed using Affymetrix Gene Chip Mouse Genome 430 2.0 Arrays. Complete gene expression profiles are available at the Gene Expression Omnibus at GSE53169. For detailed protocol of the analysis, refer to Ying and colleagues (1).

**Transcriptomic Profiling by RNA-seq and qRT-PCR**

RNA was isolated using TRIzol extraction followed by purification with the Qiagen RNeasy Kit as described previously (57). RNA-seq was performed by the Sequencing and Microarray Facility core at MD Anderson Cancer Center. Libraries were generated using Illumina’s TrueSeq Kit and were sequenced using the Illumina HiSeq2000 Sequencer. Raw read RNA-seq data were mapped to hg19 reference genome using Bowtie (58). The mapped reads were then assembled by Cufflinks (59) to generate a transcriptome assembly for each sample. After the assembly phase, Cufflinks quantified expression level of the transcriptome in each gene for each sample (i.e., FPKM, fragments per kilobase of transcript per million fragments mapped). For qRT-PCR, RNA samples were reverse-transcribed into cDNA using the High-Capacity cDNA Reverse Transcript Kit (Life Technologies). cDNA samples were subjected to qRT-PCR quantification using the High-Capacity cDNA Reverse Transcript Kit (Life Technologies). CD8 and T-cell signature genes (CD8, IL2Rγ, GZMK) were considered as coexpression of the above genes in the same tissue compartment.

**Reagents, Drugs, Neutralizing Antibodies, and Chemicals**

Ruxolitinib and tofacitinib were purchased from Selleckchem. 125I- and 111In-labeled isotopes were purchased from Cambridge Isotope Laboratories. Monoclonal neutralizing antibodies for in vitro experiments were obtained from BioXcell. For immune checkpoint blockade and IL4-neutralizing antibody treatment, anti-CD4 (clone GK1.5, BioXcell, BE0003-1) and anti-IL4 (clone 11B11, BioXcell, BP0045) antibodies or their respective horseradish peroxidase (HRP)–IgG controls were intraperitoneally administered at 200 μg per injection two times per week.

**CytTOF and Imaging Mass Cytometry**

Metal-labeled antibodies against cell-surface markers were purchased from Fluidigm. Pancreas tumor single cells were isolated using the Mouse Tumor Dissociation Kit (catalog no. 130-096-730, Miltenyi Biotec). Cells from spleen were isolated by mincing with a 5-ml syringe plunger against a 70-μm cell strainer into a 60-mm dish with RPMI medium containing 10% FBS. The cells were depleted of erythrocytes by hypotonic lysis. Peripheral blood (100 μL) was drawn using retro-orbital bleeding and depleted of erythrocytes by hypotonic lysis. Next, tumor, spleen, or blood cells were incubated with CD16/CD32 antibody (clone 2.4G2, BD Biosciences) to block FcγR binding for 10 minutes then with antibody mix for 30 minutes at room temperature. Cells were washed once and incubated with MAXPAR Nucleic Acid Intercalator-103Rh (catalog no. 201103A, Fluidigm) for 20 minutes for viability staining. Cells were fixed with 1.6% formaldehyde for 1 hour and incubated with MAXPAR Nucleic Acid Intercalator-103Rh (catalog no. 201103A, Fluidigm) for 20 minutes for viability staining. Cells were incubated with Neut352 (clone 352), CD11b (M1/70), Gr-1 (RB6-8C5), and Ly6C (HK1.4) were rare earth metal labeled antibodies was used: CD4 156Gd (clone 30-F11), CD11b (M1/70), Gr-1 (RB6-8C5), and Ly6C (HK1.4) were purchased from BioXcell. For immune checkpoint blockade and IL4-neutralizing antibody treatment, anti-CD4 (clone GK1.5, BioXcell, BE0003-1) and anti-IL4 (clone 11B11, BioXcell, BP0045) antibodies or their respective horseradish peroxidase (HRP)–IgG controls were intraperitoneally administered at 200 μg per injection two times per week.

**Single-Cell RNA-seq and Analyses**

Preparation of fresh human pancreatic tissue and dissociation into single cells: For fresh tissues undergoing single-cell transcriptomic analysis, a total of 6 patients were recruited at MD Anderson Cancer Center (MDACC) and University of Pittsburgh Medical Center (Pittsburgh, PA). Patients gave written informed consent to MDACC’s banking protocol (Lab00-396), which included consent to provide leftover tissue for future analysis. Tissues were distributed for single-cell RNA-seq under MDACC’s protocol PAL5-0014 for use/analysis. All work was done following IRB approval at both institutions (PAL5-0014, Lab08-0098, Lab05-0080, and Lab00-396). Following resection, pancreatic tissue was delivered to the laboratory on ice and dissociated into single-cell suspensions as described previously (60). Single-cell transcriptomic amplification and library prep was performed using the SureCell WTA 3’ Library Prep Kit for the ddSEQ System and as described previously. Quality analysis and quantification of cDNA libraries was performed on an Agilent 2200 Tapestation system (Tapestation) using a High Sensitivity D5000 screen tape (Agilent). Libraries were sequenced using a NextSeq 500 High Output Kit (Illumina). For a detailed protocol of sample preparation and analysis, refer to Bernard and colleagues (60). Digital microdissection of single barcoded cells determined to be lymphocytes from overall tumor cell population samples was performed on the basis of expression of CD45 and CD3 of individual cells. Location of single cells representing gene expression of interest was visualized on a dimensional reduction plot utilizing FeaturePlot. All r-sNE and heat maps were run in R v3.4.2.
(GK1.5), CD3 (145-2C11), CD8 (53-6.7), Tbet (4B10), IL17RB (9B10), and GATA3 (16E10A23) was purchased from BioLegend. Primary cells from mice were isolated with the same methods as in CyTOF. To assess cell viability, cells were incubated with 7-AAD (PanBio Biosciences) prior to FACS analysis. All samples were acquired with the LSRFortessa analyzer (Becton Dickinson) and analyzed with Flowjo software (Tree Star).

**ChIP-seq**

ChIP was performed as described previously (62) using STAT6 antibody (Cell Signaling Technology, 5397). Briefly, 5µg rabbit IgG (Santa Cruz Biotecology) or STAT6 antibody was incubated with Protein A Dynabead magnetic beads (Invitrogen) for 4 hours, followed by extensive washing to remove unbound antibody. Antibody beads were then added to the chromatin and incubated overnight.

**Cell Culture and Establishment of Primary PDAC Lines**

All the human cell lines (Hs766T, BxPc3, Patu8988T, and Patu8902) used in this study were purchased from ATCC, used below passage 25, and continuously cultured in 100 µL/mL penicillin and 100 µL/mL streptomycin. The cell lines were authenticated by short tandem repeat profiling at the Institute for Applied Cancer Sciences, MD Anderson Cancer Center. The Patu8988T, Hs766T, and Patu8902 cell lines were routinely cultured in DMEM with 10% FBS (Invitrogen). BxPc3 cell lines were routinely cultured in RPMI 1640 (Invitrogen) with 10% FBS. Primary mouse cell lines were cultured in the laboratory (AK-B6, AK192, HY668, PJK4217, PJK4298) as described previously (34) and were routinely cultured in RPMI 1640 (Invitrogen) 10% FBS (Invitrogen). For inducible KRAS-derived cell lines, 1 µg/mL of doxycycline was directly added to the media. For metabolic and metabolomic assays, 10% dialyzed FBS (Atlanta Biologicals Inc.) was used. The cell lines were Mycoplasma free, based on tests done monthly in the laboratory using Lonza’s MycoAlert Mycoplasma Detection Kit assays with confirmatory tests by PCR-based assays.

**Organoid Culture and Treatment**

Pancreatic organoids were cultured according to the manufacturer’s protocol and using PancreaCult Pancreatic Organoid media (StemCell Technology). Briefly the pancreas was isolated, followed by mechanical and enzymatic dispersion. The isolated tissue clusters were then filtered through a 70-µm filter and embedded in Matrigel (63). The Matrigel was layered with PancreaCult media supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin (Invitrogen), 10 µmol/L Rho associated kinase (ROCK) inhibitor (Stem-Cell Technology). Organoids were cultured and passaged every 5 days. For IHC, organoids were harvested and fixed in formalin following a standard protocol. Briefly, 10 µg/mL of pMD2.G were transfected using polyethylenimine (TRCN0000068188) and 5 µg of the shRNA plasmid, 5 µg of psPAX2, and 2.5 µg of pMD2.G were transfected using polyethylenimine (1 µg/µL, Polysciences #23966-2) into 293T cells plated in a 100-mm dish. Viral supernatant was collected 72 hours after transfection, centrifuged to remove any 293T cells, and filtered (0.45 µm). For transduction, viral solutions were added to cell culture medium containing 4 µg/mL polybrene; 48 hours after infection, cells were selected using 2 µg/mL puromycin and tested for gene depletion by qRT-PCR or immuno blotting. For CRISPR knockdown of JAK1, sgRNAs were purchased from Sigma (Sanger CRISPR clones). The sgRNAs were cloned into U6-grNA: PKG-puro-2A-tagBFP (Sigma Sanger Vector). The sgJAK1 sequences targeting DNA regions: ATTTTAGACAGAGCCGATG and GACTTCTATCGGTTGGCAGG. The plasmids were virally transduced into cell lines and the cells were puromycin-selected and FACS-sorted for single clones. The clones were validated by Western blot analysis for deletion of JAK1.

**Immunoblotting and Antibodies**

Media were removed and the cells were washed twice in ice-cold PBS, scraped, and collected as pellets after centrifugation at 1,700 × g for 5 minutes. The pelleted cells were incubated in RIPA buffer with proteinase and phosphatase inhibitors for 15 minutes. Lysates were then collected and centrifuged at 208,000 × g for 15 minutes at 4°C. Protein concentrations were measured using the DC Protein Assay Kit (Bio-Rad, catalog no. 5000111). SDS-PAGE and immunoblotting were performed as described previously in precast Bis-Tris 4% to 20% gradient gels (Invitrogen; ref. 64). The following antibodies were used: IL2Ry (Abcam ab180698, bioss bs-2545RF); IL33Raa1 (Abcam ab79277); pAKT-S473 (Cell Signaling Technology 9271); STAT1 (Cell Signaling Technology 9172); STAT3 (Cell Signaling Technology 4904); pSTAT3-S727 (Cell Signaling Technology 9134); pSTAT2-Y690 (4441); pSTAT5-Y705 (Cell Signaling Technology 9145); STAT6 (Abcam ab28829); STAT6 (Cell Signaling Technology); pSTAT6-Y641 (Cell Signaling Technology 56554); pSTAT5-Y694 (Cell Signaling Technology 4322); pSTAT5 (Cell Signaling Technology 9359); JAK1 (Cell Signaling Technology 3344); pJAK1-Tyr1034/1035 (Cell Signaling Technology 74129); JAK2 (Cell Signaling Technology 3230T); JAK3 (Cell Signaling Technology 8827); pJAK3 (Cell Signaling Technology 5031); HK-II (Cell Signaling Technology 2867); Enolase (Abcam ab155102); pERK-map (Cell Signaling Technology 4370); MYC (Cell Signaling Technology 5605); PIM3 (Abcam ab71321); and β-actin (Sigma-Aldrich, A2282).

**IHC and Immunofluorescence**

Harvested tissues were immediately fixed in 10% formalin overnight and embedded in paraffin. IHC was performed as described previously (62). Briefly, endogenous peroxidases were inactivated by 3% hydrogen peroxide. Nonspecific signals were blocked using 3% BSA, 10% goat serum in 0.1% Triton X-100. Tumor samples were stained with the following primary antibodies: IL2Ry (Abcam ab180698, Bioss bs-2545SR); Ki-67 (Vector Laboratories, VP-RM04); IL4R (Bioss bs2458SR); MYC (Abcam ab32077); GATA3 (Cell Signaling Technology 3344); pSTAT1-Y701 (Cell Signaling Technology 9167); pSTAT3-Y705 (Cell Signaling Technology 9145); STAT5 (Cell Signaling Technology 9352); STAT6 (Cell Signaling Technology 4322); pJAK3 (Cell Signaling Technology 5031); HK-II (Cell Signaling Technology 2867); Enolase (Abcam ab155102); pERK-map (Cell Signaling Technology 4370); MYC (Cell Signaling Technology 5605); PIM3 (Abcam ab71321); and β-actin (Sigma-Aldrich, A2282).
DAB substrate (Thermo Fisher Scientific). The slides were then counterstained with hematoxylin and mounted with mounting medium. For clinical samples, staining intensity of tissue sections was scored in a “blinded” manner by two independent pathologists.

Immunofluorescence slides were imaged with an Olympus Microscope and quantified with ImageJ.

**Glycolytic Capacity**

Cells were plated into XF Cell Culture Microplates (Seahorse Bioscience) overnight at 37°C and 5% CO₂. The next day, cells were treated with IL4 and/or IL13 for 1 hour. To measure oxygen consumption rate and ECAR, media were replaced in the Seahorse microplates with assay medium free of sodium bicarbonate and FBS, and the plate was incubated in a CO₂-free incubator for 2 hours at 37°C. Oligomycin, FCCP, and rotenone were sequentially injected into the plate for 2 minutes. The homogenate was incubated at −20°C for 20 minutes and centrifuged at 4°C for 10 minutes to partition the aqueous and organic layers. The aqueous and organic layers were combined and dried at 37°C for 45 minutes in a Across the Environmental Speed Vac system (Thermo Fisher Scientific). The extract was reconstituted in 500 μl of ice-cold methanol:water (50:50) and filtered through 3 kDa molecular filter (Amicon Ultra-3K Membrane, Millipore Corporation) at 4°C for 90 minutes to remove proteins. The filtrate was dried at 37°C for 45 minutes in a SpeedVac and stored at −80°C until mass spectrometry analysis. Prior to mass spectrometry analysis, the dried extract was resuspended in 50 μL of methanol:water (50:50) containing 0.1% formic acid and analyzed using MRM. Ten microtubes were injected and analyzed using a 6490 QQQ triple quadrupole mass spectrometer (Agilent Technologies) coupled to a 1290 series HPLC system via selected reaction monitoring (SRM). Metabolites were targeted in both positive and negative ion mode; ESI voltage was +4,000 V in positive ion mode and −3,500 V in negative ion mode. Approximately 9 to 12 data points were acquired per detected metabolite. Samples were delivered to the MS via normal phase chromatography using a Luna Amino column (4 μm, 100 A 2.1 x 150 mm, Phenomenex) at 400 mL/minute gradient spanning 80% B to 2% B over a 20-minute period followed by 2% B to 80% B for a 5-minute period and followed by 80% B for an 8-minute period to reequilibrate the column. Buffer A was comprised of 5 mmol/L ammonium acetate (pH = 9.9) in water:acetonitrile. For 13C-labeled experiments, SRMs were created for expected 13C incorporation in various forms for targeted LC/MS-MS. To assess the validity of our method for calculating isotopomers, we determined the complete isotopomer distributions for each metabolite. Data analysis was performed in quantitative analysis and estimated the percent of isotopomer incorporation using the formula [% of Incorporation = (13C/12C+13C) × 100] and subtracted with the natural abundance.

**Statistical Analysis**

GraphPad Prism software was used to conduct the statistical analysis of all data, except for qPCR data where Microsoft excel was used. Data are presented as mean ± SD except for metabolic and metabolomic experiments where data are presented as mean ± SEM. All quantitative results were assessed by unpaired Student t test after confirming that the data met appropriate assumptions (normality and independent sampling). The Student t test assumed two-tailed distributions to calculate statistical significance between groups. Unless otherwise indicated, for all in vitro experiments, three technical replicates were analyzed. Sample size estimation was done taking into consideration previous experience with animal strains, assay sensitivity, and tissue collection methodology used. For clinical samples, IHC staining intensity of tissue sections was scored in a blinded manner by a pathologist. Animal survival impact was determined by the Kaplan–Meier analysis. P < 0.05 was considered statistically significant; the P values are indicated in the figures.

**Data Availability Statement**

Source data for the main article and Supplementary Data figures are provided in the online version of this article. All other data are available from the corresponding authors upon request.

**Disclosure of Potential Conflicts of Interest**

A. Maitra has ownership interest (including patents) in Thrive Earlier Detection and Cosmos Wisdom Biotechnology, and is a consultant/advisory board member at Lustgarten Foundation for Pancreatic Cancer Research Translational Advisory Group and Pancreatic Cancer Action Network Scientific and Medical Advisory Board. R.A. DePinho is a cofounder, director, and/or advisor at Tvardi Therapeutics, Asylia Therapeutics, and Nirogy Therapeutics. No potential conflicts of interest were disclosed by the other authors.

**Authors’ Contributions**


**Acknowledgments**

We thank the MD Anderson core facilities supported by P30CA16672, including the Sequencing and Microarray Facility, Flow Cytometry and Cellular Imaging Core Facility; and S. Jiang and Z. Xu for assistance in maintenance of mouse colonies.
The Metabolic Core Facility at Baylor College of Medicine is supported by P30CA125123, CPRIT Proteomics and Metabolomics Core Facility (RP170005). In addition, this study was supported by NCI P01 CA117969 (to R.A. DePinho); NCI R01 CA225955 (to R.A. DePinho); DOD Postdoctoral Research Fellowship W81XWH-14-1-0429 (to P. Denz); K99/R00 grant 1K99 CA218891-01A1 (to P. Denz); U24 CA224020 (to A. Maitra); R01 CA218004 (to A. Maitra); R01 CA304969 (to A. Maitra). V. Bernard and D. Chakravarti were supported by the CPRIT Research Training Program (RP140106 and 170067). We thank Dr. Raghu Kalluri and colleagues for their critical review of the manuscript.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby advertised in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 9, 2019; revised December 5, 2019; accepted February 6, 2020; published first February 11, 2020.

REFERENCES


Cytokines Mediated Tumor Progression in PDAC


Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment

Prasenjit Dey, Jun Li, Jianhua Zhang, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/2159-8290.CD-19-0297

Supplementary Material
Access the most recent supplemental material at:
http://cancerdiscovery.aacrjournals.org/content/suppl/2020/02/11/2159-8290.CD-19-0297.DC1

Cited articles
This article cites 64 articles, 17 of which you can access for free at:
http://cancerdiscovery.aacrjournals.org/content/10/4/608.full#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
http://cancerdiscovery.aacrjournals.org/content/10/4/608.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerdiscovery.aacrjournals.org/content/10/4/608.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.